Promoting the safety and use of hormonal contraceptives

Journal of Women's Health

Volumn 14, Issue 1, 2005, Pages 53-60

  Gardner, Jacqueline ^a,b   Miller, Leslie ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CONTRACEPTIVE AGENT; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; GESTAGEN; GRISEOFULVIN; ORAL CONTRACEPTIVE AGENT; RIFAMPICIN; STEROID;

ARTICLE; BLOATING; CONTRACEPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG INFORMATION; DRUG MEGADOSE; DRUG PACKAGING; DRUG SAFETY; DRUG USE; EVIDENCE BASED MEDICINE; FEMALE; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH EDUCATION; HEALTH PROMOTION; HISTORY OF MEDICINE; HORMONE SUBSTITUTION; HUMAN; MIGRAINE; MORBIDITY; MORTALITY; PELVIS PAIN SYNDROME; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; THROMBOSIS; UNITED STATES; UROGENITAL TRACT DISEASE; VENOUS THROMBOEMBOLISM;

EID: 14644425451     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2005.14.53     Document Type: Article

References (57)

1. Henshaw SK. Unintended pregnancy in the United States. Fam Plann Perspect 1998;30:24, 46.
2. Chang J, Elam-Evans LD, Berg CJ, et al. Pregnancy-related mortality surveillance - United States 1991-1999. MMWR 2003;52(SS02):1.
3. Brown SS, Eisenberg L, eds. The best intentions: Unintended pregnancy and the well-being of children and families. Washington, DC: National Academy Press, 1995.
4. Koenig JD, Strauss MJ, Henneberry J, Wilson TG. The social costs of inadequate contraception. Intl J Technol Assess Health Care 1996;12:487.
5. Jones RK, Darroch JE, Henshaw SK. Contraceptive use among U.S. women having abortions in 2000-2001. Perspect Sex Reprod Health 2002;34:294.
6. Stewart FH, Shields WC, Whang AC. The 2005 United States budget: Wasteful expenditures, foregone opportunities. Contraception 2004;70:87.
7. Tone A. Devices and desires: A history of contraceptives in America. New York: Hill and Wang, 2001.
8. Stewart FH, Harper CC, Ellertson CE, Grimes DA, Sawaya GF, Trussell J. Clinical breast and pelvic examination requirements for hormonal contraception: Current practice vs. evidence. JAMA 2001;285:2232.
9. Trussell J, Stewart F, Potts M, Guest F, Ellertson C. Should oral contraceptives be available without prescription? Am J Public Health 1993;83:1094.
10. Frost JJ. Public or private providers? U.S. women's use of reproductive health services. Fam Plann Perspect 2001;33:4.
11. Gladwell M. John Rock's error. New Yorker 2000; 15:52.
12. Oakley D, Sereika S, Bogue E-L. Oral contraceptive pill use after an initial visit to a family planning clinic. Fam Plann Perspect 1991;23:150.
13. Millstein SG, Adler NE, Irwin CE Jr. Sources of anxiety about pelvic examinations among adolescent females. J Adolesc Health Care 1984;5:105.
14. Armstrong KA, Stover MA. SMART START: An option for adolescents to delay the pelvic examination and blood work in family planning clinics. J Adolesc Health 1994;15:389.
15. Hatcher RA, Nelson AL, Zieman M, et al. A pocket guide to managing contraception, 2003-2004 edition. Tiger, GA: Bridging the Gap Foundation, 2003.
16. Williams-Dean M, Potter LS. Current oral contraceptive use instructions: An analysis of patient package inserts. Fam Plann Perspect 1992;24:111.
17. Grimes DA. Dispelling OC myths and misperceptions. Dialogues Contracept 1994;4:1.
18. Mills A, Edwards IR. Venous thromboembolism and the pill: The combined oral contraceptive pill - Are poor communication systems responsible for loss of confidence in this contraceptive method? Hum Reprod 1999;14:7.
19. The Henry J. Kaiser Family Foundation. Available at www.kff.org
20. Cheng L, Gulmezoglu A, Oel C, PiaggioG, Ezcurra E, Look P. Interventions for emergency contraception. Cochrane Database Syst Rev 2004;3:CD001324.
21. U.S. Food and Drug Administration. Prescription drug products: Certain combined oral contraceptives for use as postcoital emergency contraception: Notice. Federal Register Part V, 1997;62(37):8609.
22. Preven® prescribing information. Available at www. preven.com
23. Harper C, Balistreri E, Boggess J, Leon K, Darney P. Provision of hormonal contraceptives without a mandatory pelvic examination: The first stop demonstration project. Fam Plann Perspect 2001;33:13.
24. Gardner JS, Hutchings J, Fuller TS, Downing D. Increasing access to emergency contraception through community pharmacies: Lessons from Washington state. Fam Plann Perspect 2001;33:172.
25. Shotorbani S, Gardner JS, Miller L, Downing D, Le S, Blough DK. The direct access study. Presented at Reproductive Health 2004, Annual Meeting of the Association of Reproductive Health Professionals, September 8-12, 2004, Washington, DC.
26. Zidar VM. Helping women use the pill. Population Reports, Series A, No. 10. Baltimore, MD: The Johns Hopkins University School of Public Health Population Information Program, 2000.
27. Fuller TS, Christensen DB, Williams DH. Satisfaction with prescriptive authority protocols. J Am Pharm Assoc 1996;NS36:739.
28. Grimes DA. Switching emergency contraception to over-the-counter status. N Engl J Med 2002;347:846.
29. Marciante KD, Gardner JS, Veenstra DL, Sullivan SD. Modeling the cost and outcomes of pharmacist-prescribed emergency contraception. Am J Public Health 2001;91:1443.
30. Westhoff C, Kerns J, Morroni, Cushman LF, Tiezzi L, Murphy PA. Quick start: A novel oral contraceptive initiation method. Contraception 2002;66:141.
31. Westhoff C, Morroni C, Kerns J, Murphy PA. Bleeding patterns after immediate vs. conventional oral contraceptive initiation: A randomized controlled trial. Fertil Steril 2003;79:322.
32. Clark AK, Miller SJ. The debate regarding continuous use of oral contraceptives. Ann Pharmacother 2001;35: 1480.
33. Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 2002;186:1142.
34. Miller L, Notter K. Menstrual reduction with extended use of combination and oral contraceptive pills: Randomized controlled trial. Obstet Gynecol 2001;98:771.
35. Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: A randomized trial. Obstet Gynecol 2003;101:653.
36. Pierson RA, Archer DF, Moreau M, Shangold GA, Fisher AC, Creasy GW. OrthoEvra/Evra versus oral contraceptives: Follicular development and ovulation in normal cycles and after an intentional dosing error. Fertil Steril 2003;80:34.
37. Anderson FD, Hait H, the Seasonale 301 Study Group. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003;68:89.
38. Mulders TMT, Dieben TOM. Use of the novel combined contraceptive vaginal ring for ovulation inhibition. Fertil Steril 2001;75:865.
39. Makarainen L, van Beck A, Tuomivaara L, Asplund B, Coelingh Bennink H. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. Fertil Steril 1998;69:714.
40. Döring A, Fröhlich M, Löwel H, Koenig W. Third generation oral contraceptive use and cardiovascular risk factors. Atherosclerosis 2004;172:281.
41. Direct-to-consumer advertising affects provider/patient relationship. Contracept Technol Update 1998; 19:153.
42. Van Vliet HA, Grimes DA, Helmerhorst FM, Schulz KF. Biphasic versus triphasic oral contraceptives for contraception. Cochrane Database Syst Rev 2003;2: CD003283.
43. Weisberg E. Triphasics: Have they fulfilled their promise? Curr Ther (Seaforth). 1992;33:11.
44. Hannaford PC, Webb AMC. Evidence-guided prescribing of combined oral contraceptives: Consensus statement. Contraception 1996;54:125.
45. Ortho-McNeil Pharmaceutical. OrthoTri-Cyclen: How it works. Available at www.orthotri-cyclen.com
46. Chavez A, DelConte A. A comparison of cycle control with monophasic levonorgestrel/ethinylestradiol 100 micrograms/20 micrograms versus triphasic norethindrone/ethinylestradiol 500-750-1000 micrograms/35 micrograms: A multicenter, randomized, open-label study. Eur J Contracept Reprod Health Care 1999;4:75.
47. Cedars MI. Triphasic oral contraceptives: Review and comparison of various regimens. Fertil Steril 2002; 77:1.
48. Dieppe P, Bartlett C, Davey P, Doyal L, Ebrahim S. Balancing benefits and harms: The example of non-steroidal anti-inflammatory drugs. Br Med J 2004; 329:31.
49. Ortho-McNeil Pharmaceutical. Prescribing Information, OrthoEvra®. Available at www.orthoevra.com
50. Holt VL, Cushing-Haugen KL, Daling JR. Body weight and risk of oral contraceptive failure. Obstet Gynecol 2002;99:820.
51. Truitt ST, Fraser AB, Grimes DA, Gallo MF, Schulz KF. Hormonal contraception during lactation: Systematic review of RCT. Contraception 2003;68:233.
52. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Injectable hormone contraception and bone density: Results from prospective study. Epidemiology 2002;13:581.
53. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women. Contraception 2004;69:99.
54. Pike MC, Spicer DV. Hormonal contraception and chemoprevention of female cancers. Endocr Relat Cancer 2000;7:73.
55. Dickinson BD, Altman RD, Nielsen NH, Sterling ML. Drug interactions between oral contraceptives and antibiotics. Obstet Gynecol 2001;98:853.
56. Lindsey JL, Hugin M. Drug interactions between oral contraceptives and antibiotics. Obstet Gynecol 2002; 99:841.
57. Centers for Education and Research on Therapeutics. Available at www.certs.hhs.gov